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Immunity in the absence of autoimmunity reflects “self–
 
nonself” discrimination by the immune system. The search for
mechanisms preventing autoimmunity or enabling “self”
tolerance has been at the root of immunology as evidenced
by ample conceptual framework, rhetoric, sophism, and ex-
perimental data. A full understanding of such mechanisms
would facilitate a large number of therapeutic interventions
with immunity that are too diverse to be discussed here.
Of special interest is a pathway to self tolerance that in-
 
volves regulatory or suppressor cells (also known as T
 
Reg
 
cells). Curiously, these cells exhibit an anergic phenotype,
being unable to proliferate upon TCR ligation in culture,
at the very same time that their suppressive activity is man-
ifested. This article recalls some of the early experiments
that hinted at the existence of these suppressor cells—now
a topic of intense investigation in several laboratories—and
considers their dynamic nature in vivo, which has been
newly recognized in a series of recent publications (1–4).
The new evidence shows that suppressor T cells have a
considerable intermitotic lifespan in the absence of Ag (1,
2). In addition, studies in normal mice and analyses of Ag-
 
presenting cell requirements reveal that T
 
Reg
 
, instead of being
anergic, are capable of substantial Ag-induced expansion in
vivo, accompanied by increased suppressive activity (1–4).
The new findings raise questions concerning concepts on
the pathogenesis of autoimmunity in certain gene-deficient
strains of mice such as IL-2 or IL-2 receptor (IL-2R)–deficient
mice.
 
Recessive and Dominant Tolerance.
 
There is a distinction
 
between recessive and dominant mechanisms of tolerance.
Recessive tolerance includes deletion of T cells and dele-
tion or receptor editing of B cells, whereas dominant toler-
ance is defined as that which can be transferred by a subset
of cells from a tolerant donor into an immunocompetent
host. Although initially there was some superfluous polar-
izations regarding the relevance of recessive versus domi-
nant mechanisms of tolerance (5, 6), both mechanisms ap-
pear to be essential for prevention of autoimmunity (for
review see reference 7).
Conclusive evidence of recessive tolerance indicated by
peptide–MHC complexes (8–11) or superantigens (5, 12)
in T cells and by antigens in B cells (13–16) was obtained
before that of dominant tolerance (1–10). Early indirect
and occasionally irreproducible results did not help the
course of dominant tolerance, and thus it is difficult to pin-
point data that began to convince the scientific community
of its importance. Among those certainly were thymus
transplant (17) and thymectomy (18) experiments, indicating
that the thymus might have a role in dominant tolerance:
embryonic allogeneic thymus transplants between birds
were shown to induce donor-specific tolerance to a subse-
quent wing graft (17), whereas thymectomy in the neonatal
period of mice resulted in autoimmunity (18). More con-
clusively, in the latter scenario, tolerance to self could be
 
restored by transfer of CD4
 
 
 
CD25
 
 
 
 T cells (19), whereas
in the former, at that time reproduced in mice, CD4
 
 
 
 T
cells could transfer tolerance into an immunocompetent
host (20).
 
Characterization of Regulatory T Cells.
 
Even though
CD4
 
 
 
25
 
 
 
 and CD4
 
 
 
25
 
 
 
 regulatory T cells do exist (21–
23), the CD25 marker was useful to establish some proper-
ties of polyclonal in comparison to Ag-specific regulatory T
cells. Gene expression analysis revealed high expression of
the receptors CTL4–4 and programmed death-1 (24, 25)
by regulatory T cells. However, the best marker is perhaps
the forkhead transcription factor FOXP3 (26–28), which is
expressed at high levels in regulatory CD25
 
 
 
CD4
 
 
 
 T cells
 
but not or only weakly transcribed in naive or recently ac-
tivated T cells. FOXP3 is of special interest because hu-
 
mans and mice defective in FOXP3 lack regulatory T cells
 
and suffer from autoimmunity (26, 27). Of interest is also
the glucocorticoid-induced TNFR-related protein (GITR)
(29, 30) whose ligation on CD25
 
 
 
 T cells results in loss of
suppressive activity.
In vitro analysis of polyclonal CD25
 
 
 
 cells suggested that
in terms of CD3-specific antibody- and Ag-induced prolif-
eration such cells were anergic unless supplied with high
doses of exogenous IL-2 (31). Ag-induced proliferation
was analyzed with CD25
 
 
 
 T cells from TCR transgenic
 
mice in which an 
 
  
 
TCR composed of transgenic TCR
 
 
 
and endogenous TCR
 
 
 
 chains was apparently required to
generate such cells in vivo, whereas the transgenic 
 
  
 
TCR
could be used as a vehicle to activate suppression by anti-
genic stimulation in vitro. Suppressive activity was apparent
because of inhibition of proliferation of naive T cells which
were cocultured with regulatory T cells. Such inhibition
required activation of the regulatory T cells through their
TCR, direct cell contact between suppressor and sup-
pressed T cells, and was independent of IL-10 or TGF-
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production and/or interactions of these cytokines with
their receptors. Suppression resulted in the inability of na-
ive T cells to transcribe the IL-2 gene. Apart from these
observations, the molecular nature of interactions that re-
sult in the suppression of proliferation by naive T cells has
remained obscure (31).
The same can be said for suppressive activity in vivo ex-
cept perhaps for the notion that in some models of autoim-
mune disease, such as inflammatory bowel disease precipi-
tated by injecting naive CD4
 
 
 
25
 
 
 
 cells into lymphopenic
hosts, amelioration of disease by regulatory T cells essentially
depended on their production of IL-10 (32). Suppression of
other forms of immunity, however, could proceed in the
absence of IL-10 binding to its receptor (33). Studies too di-
verse to be listed here suggested that almost all manifesta-
tions of immunity could be diminished by regulatory T cells.
 
Origin of Regulatory T Cells.
 
Transgenic mice coex-
pressing class II MHC-restricted TCRs and their agonist
ligands have been useful in delineating some pathways of
T
 
Reg
 
 generation. Initially, it was noted that such coexpres-
sion of TCR and ligand resulted in a much increased fre-
quency of CD25
 
 
 
 T
 
Reg
 
 with the transgenic TCR (34).
Follow-up studies in TCR transgenic RAG
 
 
 
/
 
 
 
 mice
showed that the interaction of the TCR with its agonist
ligand could result in CD25
 
 
 
 T
 
Reg
 
 generation in the thy-
mus when the ligand was expressed by radio-resistant cells
of the entire animal (35) or even when agonist ligand-
expressing thymic epithelium (23) was transplanted into
TCR transgenic mice. When the same ligand was expressed
exclusively on hematopoietic cells (mostly B cells), predom-
inantly CD4
 
 
 
25
 
 
 
 T
 
Reg
 
 were generated (23). Additional data
showed that naive mature T cells could become both
CD25
 
 
 
 and CD25
 
 
 
 T
 
Reg
 
 when they were exposed to ago-
nist ligands on peripheral hematopoietic tissue (23). This
somewhat bewildering variety of origins and phenotypes of
T
 
Reg
 
 suggests that the mode of agonist–ligand presentation is
of crucial importance in determining whether and if so
which phenotype of T
 
Reg
 
 is generated. A thorough in vivo
analysis of these phenotypically distinct T
 
Reg
 
 is required in
order to determine whether some of these correspond to a
distinct lineage of T
 
Reg
 
 cells in addition to T helper (T
 
H
 
)
cells and killer T cells and/or whether some of these cells
correspond to effector cells, much like so-called T
 
H1
 
 or T
 
H2
 
cells, that apparently require continuous exposure to Ag to
be maintained in a particular state of differentiation.
It is probably reasonable to focus initially on CD25
 
 
 
T
 
Reg
 
 cells generated intrathymically, since such cells are
likely to have an important role in tolerance to self. How-
ever, T
 
Reg
 
 that can be generated through antigenic expo-
sure of naive CD4
 
 
 
 T cells are of obvious interest for ther-
apeutic interventions. The latter type of cells is probably
similar to that previously generated either in vitro (36) or
after transfer of naive T cells into allogeneic hosts (37).
 
A Lineage of T
 
Reg
 
 Cells?
 
With information of how some
T
 
Reg
 
 cells are generated in vivo, one can now proceed and
ask whether Ag recognition is only required for the induc-
tion of T
 
Reg
 
 in the thymus or whether it is in fact also nec-
essary to maintain cells with that phenotype in peripheral
 
lymphoid tissue. This can best be addressed by transfer of
T
 
Reg
 
 cells with a transgenic receptor from RAG
 
 
 
/
 
 
 
 TCR
transgenic mice also expressing the relevant Ag into recipi-
ents lacking the relevant Ag. In one recent report, it could
be shown that such T
 
Reg
 
 cells could persist for several
weeks without cell division, maintaining their cell surface
phenotype and the ability to suppress proliferation of naive
T cells in vitro (1). This agrees well with the finding that
some CD25
 
 
 
 T
 
Reg
 
 from normal mice that express high lev-
els of CD62L can survive as quiescent cells for 
 
 
 
70 d with-
out changing their phenotype (2). These data strongly ar-
gue that at least some of the CD25
 
 
 
 T
 
Reg
 
 cells belong to a
lineage with a “suppressor program” that remains stable
over long periods of time rather than representing Ag-depen-
dent short-lived effector cells. In the same transfer experi-
ments, some recently activated T
 
Reg
 
 do not survive nearly
as well (2), and it needs to be established whether this is be-
cause of prior prolonged exposure to Ag.
 
How Anergic Are Different T
 
Reg
 
 Cells In Vivo?
 
Some-
what unexpected from the in vitro data, several groups ob-
served independently (1–4) that in normal nonlym-
phopenic mice T
 
Reg
 
 cells can be stimulated by Ag to
proliferate almost as strongly as naive CD4
 
 
 
 T cells such
that a marked accumulation of T
 
Reg
 
 can be observed in Ag
draining LNs. During the proliferative phase, T
 
Reg
 
 cells up-
regulate CD25 expression even further. After 8 d of con-
tinuous expansion, such cells are still anergic in the in vitro
assay and able to suppress the proliferation of naive T cells.
What is the reason for this discordant in vitro and in vivo
behavior? Two obvious possibilities exist. First, there may
be more IL-2 available in vivo allowing for better prolifera-
tion. This would be consistent with the notion that high
doses of IL-2 were permissive for T
 
Reg
 
 proliferation in
vitro. On the other hand, in the standard culture condi-
tions DCs were absent, and presentation of Ag by those
cells in vivo may be key to inducing proliferation. These
possibilities were to some extent addressed by one of the
reports (3): stimulation of cocultures of T
 
Reg
 
 on naive T
cells with activated DCs resulted in proliferation of naive
cells, presumably because such culture conditions make na-
ive T cells insensitive to suppression by T
 
Reg
 
 (38). This
could represent an important observation that may explain
how naive T cells can escape suppression when presented
with Ag on activated DCs. However, although this has
been described in vitro (3, 38), the in vivo relevance of the
observation is not clear as in vivo responses of naive T cells
to Ag presented by fully activated DCs were strongly sup-
pressed by regulatory T cells (39). Interestingly, under the
in vitro conditions, not only naive T cells but also T
 
Reg
 
proliferated perhaps in an IL-2–dependent manner, since
the proliferation could be (incompletely) inhibited by IL-2
receptor antibodies in spite of the fact that IL-2 production
by the T
 
Reg
 
 cells was below the level of detection (36). In
vitro stimulation by mature DCs may be required for some
minimal IL-2 production by T
 
Reg
 
, whereas in vivo the
combined action of Ag presentation by DCs and the avail-
ability of exogenous IL-2 may help T
 
Reg
 
 expansion. Here it
should be emphasized that even in vivo T
 
Reg
 
 produce littleT
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IL-2 themselves (1). Thus, at least some T
 
Reg
 
 are capable of
marked Ag-induced expansion in vivo in spite of their an-
ergy in vitro. This does not necessarily apply to all T
 
Reg
 
, es-
pecially those that are constantly stimulated by Ag in vivo
such as CD25
 
 
 
 and CD25
 
 
 
 T cells from mice that express
Ag on hemopoietic cells. The proliferation of such cells
could not be efficiently rescued by IL-2 in vitro, and they
did not expand when coinjected with Ag-pulsed DCs in
vivo (23). On the other hand, the potential of not recently
activated T
 
Reg
 
 to expand in vivo seems somewhat limited:
it was noted that when T
 
Reg
 
 were injected into mice that
expressed the relevant Ag under control of the insulin pro-
moter they initially expanded significantly in pancreatic
LNs but eventually disappeared by day 11, perhaps due to
cell death (2). Curiously, in a different model T
 
Reg
 
 did not
disappear up to day 14 (4).
The important question whether or not Ag-induced
proliferation of T
 
Reg
 
 in vivo requires activated DCs was
likewise addressed in various ways. Recent reports agree
that there is no necessity for activation of DCs since intra-
venous injection of soluble protein or presentation by tissue
such as pancreatic islet cells was sufficient to induce prolif-
eration, which in the latter case was more limited and oc-
curred presumably after uptake of Ag by DCs (1–4). This
suggests that Ag presentation by immature DCs does not
only induce deletion of naive T cells after a short prolifera-
tive wave (10, 11, 39, 40) but can induce marked expan-
sion of T
 
Reg
 
 cells which, however, eventually may disap-
pear when Ag is continuously present (2).
 
Does Expansion of T
 
Reg
 
 In Vivo Require IL-2?
 
The ap-
parent IL-2 dependence of T
 
Reg
 
 expansion in vitro could
suggest that this cytokine plays also an essential role of T
 
Reg
 
expansion in vivo, and recent data in IL-2 and IL-2R–defi-
cient mice are consistent with that notion (41). IL-2R 
 
 
 
chain knockout mice suffer from autoimmunity that can be
cured if the IL-2R 
 
 
 
 chain is expressed as a transgene in
such mice in the thymus only. Such IL-2R
 
 
 
 transgenic IL-
2R
 
 
 
 
 
/
 
 
 
 mice when compared with IL-2R
 
 
 
 
 
/
 
 
 
 mice have
more CD4
 
 
 
25
 
 
 
 cells in both the thymus and secondary
lymph organs presumably because of increased emigration
from the thymus. Autoimmunity in IL-2R
 
 
 
 
 
/
 
 
 
 mice can
also be cured by transfer of CD4
 
 
 
25
 
 
 
 cells from normal
mice which expand in the host (41, 42). However, transfer
of IL-2R
 
 
 
 transgenic peripheral CD4
 
 
 
25
 
 
 
 cells from IL-
2R
 
 
 
 
 
/
 
 
 
 mice, which no longer express the IL-2R
 
 
 
 chain,
into IL-2R
 
 
 
 
 
/
 
 
 
 recipients does not cure disease, and these
cells do not expand presumably because they have lost IL-
2R transgene expression and thus cannot utilize IL-2. Al-
though it is not clear to what extent the expansion of T
 
Reg
 
is Ag driven in these particular experiments, these data raise
the possibility that Ag-induced in vivo expansion of T
 
Reg
 
likewise requires IL-2. In addition, IL-2 may have an es-
sential role in the generation of T
 
Reg
 
 in the thymus, since
IL-2
 
 /  mice were reported to have no CD4 25  cells in
the thymus (42). It is of interest that even in the presence of
IL-2 the expansion of TReg is limited, perhaps by a homeo-
static mechanism that prevents suppression of the entire
immune system (42).
In Vivo Suppression and Cytokine Production by TReg.
Analogous to the in vitro coculture experiments, one can
now begin to analyze in which way TReg interfere with the
generation of T effector cells by coinjecting TReg with na-
ive T cells with known Ag specificity into normal mice and
following their proliferation and differentiation (1–4).
When this was done with an initially low frequency of both
TReg and naive T cells representing each 0.3% of CD4  T
cells, both populations expanded in an Ag-dependent man-
ner and produced typical patterns of cytokines, the TReg
mostly IL-10 and the naive T cells IL-2 and  -interferon.
At later points in time, the accumulation of effector cells
derived from naive T cells was severely hampered by the
expanding TReg cells such that by day 8 after antigenic stim-
ulation the latter represented the dominant population. The
diminished numbers of descendants of naive T cells when
briefly stimulated with PMA and ionomycin in vitro, how-
ever, exhibited no significant changes in cytokine content,
neither IL-2 nor IFN-  (1). Thus, contrary to in vitro stud-
ies, no influence of TReg on commitment of T cells to cyto-
kine secretion, i.e., immunomodulation, could be ob-
served. If such immunomodulated cells were to exist in
vivo, they may have been quickly removed by cell death or
migrated from the Ag draining LN even though no signifi-
cant changes were observed in nondraining nodes. Thus on
the basis of these data, a reevaluation of the effects of TReg
activity on naive T cells seems warranted. The initial lag
phase in the inhibition of naive T cell expansion may be re-
lated to the fact that in vivo, not unlike in vitro, close prox-
imity of TReg and their targets is required also and that both
populations must reach a certain frequency before their ef-
fective interaction. The secretion of IL-10 may help immu-
nosuppression under certain but not other conditions and
other forms of suppression, that may include competition
for growth factors, may represent the most effective way in
which regulatory T cells interfere with immunity (1).
Defects in Recessive or Dominant Tolerance in IL-2 /  and
IL-2R /  Mice? The fact that TReg expansion is required
for effective immunosuppression and that the expansion
may require IL-2 raises the question whether the autoim-
munity in IL-2 /  or IL-2R /  mice is due to failure of
recessive or dominant tolerance. Initially, it was suggested
that IL-2 was necessary to make activated T cells suscepti-
ble to Fas-dependent apoptosis (43–45), and thus it was
considered that defects in activation-induced cell death
were responsible for autoimmunity in IL-2 /  or IL-2R / 
mice. It has been realized, however, that the proapoptotic
member of the Bcl2 family, Bim, rather than Fas is essential
for activation-induced cell death in vivo (46, 47), whereas
Fas appears to have a major role in apoptosis in vitro. Thus,
there is ample reason to suspect that defects in dominant
rather than recessive tolerance are responsible in mice that
cannot utilize IL-2 because of genetic defects. As discussed
above, this scenario is strongly supported by the fact that
CD4 25  regulatory T cells with intact but not deficient
IL-2 receptors (ILR  / ) can cure the autoimmune disease
in IL-2R  /  mice (41). Thus, these data warrant reexam-
ination of conclusions on the mechanisms of autoimmunityT
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in various gene-deficient mice, including Fas-deficient
mice, since it is in fact not even clear whether the lym-
phadenopathy and autoantibody production in Fas-defi-
cient mice is due to defects in Fas-dependent apoptosis in
T cells (48).
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